Literature DB >> 22547014

Decreased total MKP-1 protein levels predict poor prognosis in breast cancer.

Ming-Feng Hou1, Chien-Wei Chang, Fang-Ming Chen, Shen-Nien Wang, Sheau-Fang Yang, Po-Han Chen, Jinu-Huang Su, Yao-Tsung Yeh.   

Abstract

BACKGROUND: MKP-1 dephosphorylates and inactivates MAPKs, whose constitutive activations have been associated with human cancers.
RESULTS: We found that total MKP-1 protein levels were decreased in 63.7 % of breast cancer tissues compared with the paired noncancerous breast tissues. Decreased MKP-1 protein levels were correlated with increased tumor stage and positive recurrence and were associated with poor survival, even when using a multivariate Cox regression model. Intriguingly, nuclear MKP-1 staining was positively correlated with ER status. In vitro, tamoxifen increased MKP-1 expression in ER-positive but not ER-negative breast cancer cells. ER-specific siRNA was able to attenuate tamoxifen-induced MKP-1 expression. Furthermore, tamoxifen prolonged the duration of MKP-1 elevation and the binding time of ER to the promoter of the MKP-1/DUSP-1 gene compared with estrogen.
CONCLUSIONS: Our results suggest that alterations of MKP-1 may serve as a prognostic factor in breast cancer. In addition, the regulation of MKP-1 may be related to the ER.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22547014     DOI: 10.1007/s00268-012-1608-y

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  29 in total

Review 1.  Nuclear receptor-mediated transactivation through interaction with Sp proteins.

Authors:  Stephen Safe; Kyounghyun Kim
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2004

Review 2.  Mitogen-activated protein kinases in apoptosis regulation.

Authors:  Teiji Wada; Josef M Penninger
Journal:  Oncogene       Date:  2004-04-12       Impact factor: 9.867

3.  Serum adiponectin levels in cholesterol and pigment cholelithiasis.

Authors:  S-N Wang; Y-T Yeh; M-L Yu; C-L Wang; K-T Lee
Journal:  Br J Surg       Date:  2006-08       Impact factor: 6.939

4.  Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival.

Authors:  Wei Wu; Travis Pew; Min Zou; Diana Pang; Suzanne D Conzen
Journal:  J Biol Chem       Date:  2004-12-07       Impact factor: 5.157

Review 5.  Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.

Authors:  Gary L Johnson; Razvan Lapadat
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

6.  Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma.

Authors:  Carsten Denkert; Wolfgang D Schmitt; Stefan Berger; Angela Reles; Sören Pest; Antje Siegert; Werner Lichtenegger; Manfred Dietel; Steffen Hauptmann
Journal:  Int J Cancer       Date:  2002-12-10       Impact factor: 7.396

7.  Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance.

Authors:  George W Small; Yue Y Shi; Linda S Higgins; Robert Z Orlowski
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

Review 8.  Dual-specificity MAP kinase phosphatases (MKPs) and cancer.

Authors:  Stephen M Keyse
Journal:  Cancer Metastasis Rev       Date:  2008-06       Impact factor: 9.264

9.  MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.

Authors:  S Chattopadhyay; R Machado-Pinilla; C Manguan-García; C Belda-Iniesta; C Moratilla; P Cejas; J A Fresno-Vara; J de Castro-Carpeño; E Casado; M Nistal; M Gonzalez-Barón; R Perona
Journal:  Oncogene       Date:  2006-02-06       Impact factor: 9.867

10.  A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells.

Authors:  Andreas Vogt; Peter R McDonald; Aletheia Tamewitz; Rachel P Sikorski; Peter Wipf; John J Skoko; John S Lazo
Journal:  Mol Cancer Ther       Date:  2008-02-01       Impact factor: 6.261

View more
  4 in total

1.  DUSP1 alleviates cardiac ischemia/reperfusion injury by suppressing the Mff-required mitochondrial fission and Bnip3-related mitophagy via the JNK pathways.

Authors:  Qinhua Jin; Ruibing Li; Nan Hu; Ting Xin; Pingjun Zhu; Shunying Hu; Sai Ma; Hong Zhu; Jun Ren; Hao Zhou
Journal:  Redox Biol       Date:  2017-11-06       Impact factor: 11.799

2.  Hsa-miR-202-3p, up-regulated in type 1 gastric neuroendocrine neoplasms, may target DUSP1.

Authors:  Dou Dou; Yan-Fen Shi; Qing Liu; Jie Luo; Ji-Xi Liu; Meng Liu; Ying-Ying Liu; Yuan-Liang Li; Xu-Dong Qiu; Huang-Ying Tan
Journal:  World J Gastroenterol       Date:  2018-02-07       Impact factor: 5.742

3.  The suppression of DUSP5 expression correlates with paclitaxel resistance and poor prognosis in basal-like breast cancer.

Authors:  Tieju Liu; Huizhi Sun; Shiqi Liu; Zhao Yang; Linqi Li; Nan Yao; Siqi Cheng; Xueyi Dong; Xiaohui Liang; Chen Chen; Yi Wang; Xiulan Zhao
Journal:  Int J Med Sci       Date:  2018-05-16       Impact factor: 3.738

4.  Transcriptome Analysis of Liver Cancer Cell Huh-7 Treated With Metformin.

Authors:  Chun-Qing Li; Zhi-Qin Liu; Sha-Sha Liu; Gao-Tao Zhang; Li Jiang; Chuan Chen; Du-Qiang Luo
Journal:  Front Pharmacol       Date:  2022-03-23       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.